CUE Stock Overview
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Cue Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$3.25 |
| 52 Week Low | US$0.45 |
| Beta | 1.8 |
| 11 Month Change | -35.03% |
| 3 Month Change | 32.55% |
| 1 Year Change | -58.20% |
| 33 Year Change | -92.04% |
| 5 Year Change | -91.39% |
| Change since IPO | -91.23% |
Recent News & Updates
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Shareholder Returns
| CUE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.1% | -3.7% | 0.3% |
| 1Y | -58.2% | 15.2% | 31.1% |
Return vs Industry: CUE underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: CUE underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CUE volatility | |
|---|---|
| CUE Average Weekly Movement | 26.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CUE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CUE's weekly volatility has increased from 18% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 53 | Dan Passeri | www.cuebiopharma.com |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
Cue Biopharma, Inc. Fundamentals Summary
| CUE fundamental statistics | |
|---|---|
| Market cap | US$65.25m |
| Earnings (TTM) | -US$44.61m |
| Revenue (TTM) | US$9.53m |
6.8x
P/S Ratio-1.4x
P/E RatioIs CUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUE income statement (TTM) | |
|---|---|
| Revenue | US$9.53m |
| Cost of Revenue | US$37.29m |
| Gross Profit | -US$27.76m |
| Other Expenses | US$16.85m |
| Earnings | -US$44.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | -291.24% |
| Net Profit Margin | -468.02% |
| Debt/Equity Ratio | 20.9% |
How did CUE perform over the long term?
See historical performance and comparison